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Zika virus (ZIKV), chikungunya virus (CHIKV), and dengue virus (DENV) have been
associated with clinical presentations that involve acute neurological complaints. In
the current study, we identified ZIKV, CHIKV, and DENV in cerebrospinal fluid (CSF)
samples from patients admitted to the Hospital Luis Vernaza (Guayaquil, Ecuador) to
the Emergency Room or the Intensive Care Unit, with neurological symptoms and/or
concern for acute arboviral infections. Viral RNA from one or more virus was detected in
12/16 patients. Six patients were diagnosed with meningitis or encephalitis, three with
Guillain–Barré Syndrome, and one with CNS vasculitis. Two additional patients had a
systemic febrile illness including headache that prompted testing of CSF. Two patients,
who were diagnosed with encephalitis and meningoencephalitis, died during their
hospitalizations. These cases demonstrate the breadth and significance of neurological
manifestations associated with ZIKV, CHIKV, and DENV infections.
Keywords: Zika virus, Guillain–Barre syndrome, meningitis, chikungunya virus, dengue virus, cerebrospinal fluid,
molecular diagnosis
INTRODUCTION
Zika virus (ZIKV) is an arthropod-borne virus (arbovirus) of the genus Flavivirus (family
Flaviviridae) that is transmitted by the same mosquito vectors as chikungunya virus (CHIKV)
and dengue virus (DENV; Waggoner and Pinsky, 2016). Amidst the current outbreak
in the Americas, ZIKV has been associated with severe neurological manifestations in
adults, including Guillain–Barré syndrome (GBS; Cao-Lormeau et al., 2016; Dirlikov et al.,
2016; do Rosario et al., 2016; Dos Santos et al., 2016), acute myelitis (Mecharles et al.,
2016), and encephalitis (Carteaux et al., 2016; Soares et al., 2016). GBS has been the
best studied neurological presentation in adults, and the association between recent ZIKV
infection and GBS has been principally demonstrated in studies that have relied on serologic
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testing for ZIKV diagnosis (Cao-Lormeau et al., 2016; Dos Santos
et al., 2016). This may be due to difficulties in diagnosing acute
ZIKV infections in adults, as detection of ZIKV in CSF has been
infrequently reported (Parra et al., 2016; Rozé et al., 2016; Siu
et al., 2016; Zambrano et al., 2016) and serologic testing may be
difficult to interpret in DENV endemic regions (Waggoner and
Pinsky, 2016).
Zika virus, CHIKV, and DENV have co-circulated in many
regions of the Americas over the past year. While the neurological
complications of ZIKV infection have been the cause of much
concern during this outbreak, less attention has been paid to
the neurological manifestations associated with acute or recent
CHIKV and/or DENV infections (Solomon et al., 2000; Gerardin
et al., 2016). Clinical diagnosis cannot reliably distinguish
symptomatic infections caused by these viruses (Waggoner
et al., 2016b), which complicates the interpretation of results
from studies based on reported Zika cases (Dos Santos et al.,
2016) or patients with compatible symptoms (Parra et al.,
2016). Additionally, co-infections between these viruses may
be common in certain settings (Villamil-Gomez et al., 2016;
Waggoner et al., 2016b; Zambrano et al., 2016), and the detection
of co-infections in cases of CNS disease has not been well
described (Zambrano et al., 2016).
The first cases of ZIKV infection in Ecuador were reported
in January 2016 in two returned travelers. Shortly thereafter,
autochthonous transmission was documented in the country.
CHIKV was introduced into Ecuador in 2014, and DENV
has been endemic in Ecuador since 1988. Guayaquil, located
on the Pacific Ocean, is the largest city in Ecuador, and has
a high incidence of arboviral infections. During 2016, ZIKV,
CHIKV, and DENV co-circulated in Guayaquil. In the current
study, we sought to determine the incidence of ZIKV, CHIKV,
and/or DENV detection in cerebrospinal fluid (CSF) from adult
patients admitted with neurological symptoms to the Hospital
Luis Vernaza, the largest medical center in Guayaquil.
MATERIALS AND METHODS
Clinical Samples
A convenience set of CSF samples from 16 patients was tested
for this study. Patients had been admitted to the Hospital Luis
Vernaza in Guayaquil, Ecuador and had CSF collected as part of
routine care. Patients were admitted from February 1 to August
31, 2016 and were initially evaluated by a neurologist or hospital
staff physician. If lumbar puncture was warranted, the procedure
was performed and CSF was sent to the Molecular Biology
Laboratory and the Hospital Central Laboratory. Following the
performance of testing requested by care providers, remaining
CSF was stored at −20◦C until RNA extraction could be
performed. When possible, urine and blood samples collected on
the day of CSF collection were also tested.
In addition to molecular testing for ZIKV, CHIKV, and DENV
(described below), CSF samples were evaluated by the following
methods: Gram stain, bacterial culture (up to 48 h if no growth
was observed), Ziehl–Neelsen stain, and India ink stain. CSF
PCRs were also performed for herpesviruses [HSV 1, 2, and 6;
cytomegalovirus; Epstein–Barr virus (EBV); and varicella zoster
virus, all from DiaPro, Milan, Italy], toxoplasma gondii (DiaPro,
Milan, Italy), enterovirus and tuberculosis (Cepheid, Sunnyvale,
California) according manufacturer recommendations. Clinical
data and the results of additional laboratory tests (e.g., blood
cell counts, biochemical, and microbiological results from CSF),
electromyography, and radiographic studies were obtained from
the medical record. Patients provided written informed consent
for diagnostic procedures and laboratory testing recommended
by their care providers. For patients with altered cognition,
consent was obtained from a surrogate decision maker. The
study protocol was reviewed and approved by the Comité de
Investigación at the Hospital Luis Vernaza.
Sample Processing and Arbovirus
Testing
RNA was extracted from140 µl CSF for all patients using
the QIAamp Viral RNA Mini kit (Qiagen, Hilden, Germany)
and a 60-µL elution volume, according to the manufacturer’s
instructions. RNA was also extracted from serum (n = 4) and
urine (n = 3) samples, using the same protocol and specimen
volumes. RNA was stored at−20◦C until testing.
All samples were tested for ZIKV, CHIKV, and DENV using
the ZCD assay. This is an internally controlled, multiplex real-
time reverse transcription PCR (rRT-PCR), which was performed
on a Cobas Z 480 instrument (Roche Diagnostics) using the users
defined format, as described previously (Waggoner et al., 2016a;
Zambrano et al., 2016). ZIKV, CHIKV, and DENV are detected
in separate channels of the Cobas Z, and an assay for RNase
P detection serves as a heterologous, intrinsic internal control.
A sample was considered positive for a given target (any virus
or RNase P) if an exponential curve crossed the instrument-
defined threshold in the appropriate channel prior to or at cycle
40. Samples negative for all three viruses and with a positive
result for RNase P were considered negative. Each run of the ZCD
assay included a no-template control (water), a negative control
(positive for RNase P but negative for any pathogen), and positive
controls for ZIKV, CHIKV, and DENV.
RESULTS
Cerebrospinal fluid samples from 16 patients were included in
this study (Table 1). The mean patient age was 42.1 years (sd
17.4) and 10 patients (62.5%) were male. Results of testing using
the ZCD assay are shown in Table 1. Twelve samples (75.0%)
tested positive for one or more viruses: ZIKV was detected in
nine patients, CHIKV in 11, and DENV in 5. Three patients had
evidence of a mono-infection, and nine patients had evidence
of a co-infection with two (n = 5) or all three viruses (n = 4;
Table 1). Viral RNA was detected as late as 14 days post-symptom
onset. Four individuals tested negative in the ZCD assay but had
detectable RNase P, indicating sufficient nucleic acid extraction
and the absence of PCR inhibitors.
Clinical information on the 12 positive patients is shown
in Table 2. Six patients were diagnosed with meningitis
or encephalitis, three patients had GBS, and one patient
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TABLE 1 | Demographic information and ZCD assay results from CSF for 16 patients.
Patient Age (years) Gender Days post-symptom onset ZCD assay results
ZIKV CHIKV DENV RNase P
1 18 Male 5 + + + +
2 16 Male 3 − − − +
3 23 Male 1 + + + +
4 54 Female 6 + + − +
5 44 Male 9 + + − +
6 25 Female 14 + + + +
7 47 Male 1 + + − +
8 28 Female 6 + + − +
9 65 Female 1 − − − +
10 48 Male 14 − + + +
11 48 Male 15 − − − +
12 60 Female 5 − + − +
13 53 Female 14 − + − +
14 62 Male 1 + + + +
15 21 Male 8 + − − +
16 62 Male 30 − − − +
TABLE 2 | Clinical information for 12 patients with positive ZCD assay results from CSF.
Patient Signs and symptoms Diagnosis Additional positive results
1 Upper respiratory tract infection, followed by asthenia,
leg paresthesias, weakness, dysarthria, decreased
muscular strength in legs and left arm (3/5),
hyporeflexia, hyporeactive pupils.
Guillain–Barré syndrome. Symmetric motor
polyneuropathy
None
3 Encephalopathy, asthenia, oliguria Encephalitis None
4 Fever, headache, and lumbar back pain; followed by
paresthesias in her hands, feet, and face; left facial
paralysis; and dysarthria.
Guillain–Barré syndrome. Motor and sensory
axonal neuropathy
None
5 Nosocomial fever of unknown origin, arthralgia Fever secondary to ZIKV-CHIKV co-infection None
6 Fever, nausea, vomiting and diarrhea; followed by
generalized tonic-clonic seizure, headache, ptosis of
the eyelids, neck stiffness.
Meningitis None
7 Altered wakefulness, generalized tremors and walking
difficulties. Fever and tonic-clonic seizure.
Encephalitis None
8 Fever, generalized weakness, asthenia, anorexia,
headache, neck stiffness
Meningitis HIV/AIDS
Toxoplasmosis detected by CSF PCR
10 Fever, vomiting, diarrhea and headache Meningitis HIV/AIDS
Cryptococcus detected by India Ink
and culture
12 Cold symptoms followed by fever, chills, headache,
neck stiffness, nausea, vomiting, sensory impairment,
photophobia
Meningoencephalitis EBV detected by CSF PCR
13 Polyarthralgia, fever and headache Chikungunya fever Self-reported history of chikungunya
14 Fever, sweating, paraplegia, arreflexia, dyspnea,
decreased muscular strength in arms
Guillain–Barré syndrome None
15 Blurred vision in left eye followed by blindness,
dysphasia, weakness and decreased muscular strength
in legs and arms, lack of sphincter control.
Cerebral vasculitis None
was diagnosed with CSF vasculitis. In two additional cases,
patients had a systemic febrile illness related to a ZIKV-
CHIKV co-infection or CHIKV mono-infection. Two patients
with meningitis had AIDS and were also diagnosed with
toxoplasmosis and cryptococcosis, respectively, during their
admissions. Patients 3 and 12 were both admitted to the intensive
care unit with encephalitis and meningoencephalitis, respectively,
and died during their hospitalization.
Cerebrospinal fluid findings for eight patients who had ZIKV,
CHIKV, and/or DENV detected in CSF without another potential
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TABLE 3 | Cytological analysis for patients with ZIKV, CHIKV, and/or DENV detected from CSF without another potential cause for their presentation.
Patient∗ Leukocyte count (per µl) Neutrophils (%) Mononuclear cells (%) Glucose (mg/dl) Protein (mg/dl) LDH (U/l)
1 13 38.5 61.5 55 33.3 11
3 5 40 60 79.1 50.9 27
4 3 66.7 33.3 57.1 120.2 16
6 245 18 82 56.1 20.3 25
7 6 83.3 16.7 36.6 76.0 43
13 142 4.9 95.1 31.3 62.0 66
14 2 50 50 68 278 22
15 1 0 100 59.4 54 22
∗For patient 5, there was clinical concern for a post-operative infection, though no growth was observed in bacterial cultures.
cause for their symptoms are shown in Table 3. Five of eight
patients had an elevated white blood cell (WBC) count in
the CSF (≥5 cells/µL), and patients 6 and 13 had marked
elevations to 245 and 142 cells/µL, respectively. Three patients
with CSF leukocytosis had a predominance of mononuclear
cells. Patient 7, who presented 1 day post-symptom onset, had a
neutrophil predominance. Five patients had elevated CSF protein
(>40 mg/dl), including all three patients with normal CSF WBC
counts. Mild elevations in CSF lactate dehydrogenase (LDH) and
decreases in glucose were seen, together, in patients 7 and 13.
While both patients had CHIKV infections, these changes did not
correlate with clinical presentation or disease severity.
In four patients (1, 3, 4, and 12), serum and/or urine
samples were available from the same day as the CSF sample.
Results from CSF and serum were concordant for 10/12 (83.3%)
possible comparisons. In patient 3, DENV was detected in CSF
and not serum; in patient 12, ZIKV was detected in serum
(and urine) but not in CSF. Patient 4 had concordant results
in each specimen type (ZIKV-CHIKV co-infection). Finally
in Patient 1, urine tested negative for DENV and CHIKV,
though ZIKV, CHIKV, and DENV were all detected in serum
and CSF.
Radiographic Findings and
Electromyography Testing
Electromyography findings in patients diagnosed with GBS were
consistent with the following: motor axonal polyneuropathy
(Patient 1); motor and sensory axonal neuropathy and secondary
acute demyelination (Patient 4); demyelinating polyneuropathy
and secondary axonal damage (Patient 14). Patient 1 had a brain
MRI performed, which was normal.
Three additional patients had abnormalities noted on CNS
imaging. Patient 3 had a head computed tomography scan
showing symmetric alterations in the lenticular nucleus that
were confirmed by magnetic resonance angiography as ischemic
alterations of vasculitic origin affecting the lenticular nucleus,
periventricular thalamic nucleus and the periaqueductal gray
matter. Patient 7 had discrete changes detected in the lenticular
nucleus by MRI (T2-flair images) as well as electroencephalogram
findings consistent with cortical dysfunction. Patient 15 had
multiple abnormalities on brain MRI affecting the periventricular
regions, the protuberance and the cerebral peduncle. These did
not extend to contiguous structures, and findings were most
consistent with cerebral vasculitis.
DISCUSSION
In the current paper, we present 16 patients who were admitted
to a single center in Guayaquil, Ecuador, with neurological
symptoms and/or concern for arboviral illness. We identified
twelve individuals with detectable RNA from ZIKV, CHIKV,
and/or DENV in CSF. Notably, co-infections were identified
in CSF relatively frequently (9/12 positive cases). RNA was
detectable early in the course of neurological symptoms, which
is consistent with a recent report describing detection of ZIKV
RNA in the CSF of a patient with GBS on day 3 (Siu et al., 2016).
Recent reports describing GBS in the setting of ZIKV
infections have principally relied on serologic testing and/or
clinical symptoms for the detection of Zika cases. In a report
by Parra et al. (2016), 66/68 patients with GBS in Colombia had
symptoms of a recent ZIKV infection. Of 42 patients tested by
RT-PCR, only 17 (25% of the total population) were positive for
ZIKV, including 16 urine samples and 3 CSF samples. All patients
tested negative for DENV by RT-PCR (Parra et al., 2016). In
our experience, clinical symptoms do not accurately differentiate
patients with ZIKV, CHIKV, and/or DENV (Waggoner et al.,
2016b). Reliance on reported symptoms without diagnostic
confirmation may over-emphasize the association between GBS
and ZIKV mono-infection, and in our series, the three cases of
GBS occurred in the setting of ZIKV co-infections with CHIKV
and/or DENV.
It is notable that in the current series, the most severe cases
involved patients with encephalitis and meningoencephalitis.
Both patients tested positive for CHIKV, including patient 12
who only tested positive for CHIKV, and both patients died in
the intensive care unit. A small number of deaths have been
reported in the setting of ZIKV infection, though these cases have
typically presented with anemia and severe thrombocytopenia,
rather than neurological manifestations (Sarmiento-Ospina et al.,
2016; Swaminathan et al., 2016).
Increased detection in our case series may have resulted from
utilization of a multiplex rRT-PCR with improved sensitivity for
ZIKV and DENV detection (Waggoner et al., 2016a) compared
to assays that were used in studies referenced here (Cao-Lormeau
et al., 2016; Dirlikov et al., 2016; Parra et al., 2016). This facilitates
the testing of all samples for ZIKV, CHIKV, and DENV in a
single reaction, where testing with separate assays may not be
performed following a single positive result. Arbovirus RNA was
detected in CSF as late as 14 days post-symptom onset. As this
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specimen type is rarely tested in the setting of acute infections
with these pathogens, the duration of RNA detection in CSF
is unknown. However, we do not favor that viral detection in
these cases was related to past infections, given the paucity of
co-infections reported from CSF to date.
Finally, two patients with HIV and AIDS were identified
who had ZIKV-CHIKV and CHIKV-DENV co-infections,
respectively. Both patients were severely ill, but the contribution
of arboviral infection to the clinical picture, in the setting
of documented opportunistic infections, is unclear. Only a
single case of ZIKV in an HIV-infected patient has been well
documented in the literature (Calvet et al., 2016). For DENV,
however, AIDS does not appear to be a risk factor for the
development of severe disease (Watt et al., 2003), and it is likely
that ZIKV, CHIKV, and DENV were incidentally detected in these
two cases. Given the small sample size and observational nature
of the current study, further conclusions regarding the impact of
co-infections on disease manifestations cannot be made, but this
warrants further study in endemic regions.
CONCLUSION
Our data demonstrate the breadth of neurological manifestations
associated with ZIKV, CHIKV, and/or DENV infections. All
three viruses should be considered in the differential diagnosis
for patients with new neurological symptoms in endemic
areas of the world, and these data further support the use
of a multiplex diagnostic for ZIKV, CHIKV, and DENV
testing.
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